Published in Endocrinology on May 01, 1995
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Kinase cascades regulating entry into apoptosis. Microbiol Mol Biol Rev (1997) 1.39
Extracellular matrix remodeling and the regulation of epithelial-stromal interactions during differentiation and involution. Kidney Int Suppl (1996) 1.07
Ki-67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol (1996) 1.06
Gene targeting to the stroma of the prostate and bone. Differentiation (2008) 0.84
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell (1982) 3.54
Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol (1982) 3.47
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A (1993) 3.32
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst (1998) 3.13
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 2.70
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69
The 50- and 58-kdalton keratin classes as molecular markers for stratified squamous epithelia: cell culture studies. J Cell Biol (1983) 2.58
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. J Cell Biol (1993) 2.48
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study. Brain (1975) 2.20
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol (2001) 2.07
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (2001) 2.04
Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res (1993) 1.92
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. EMBO J (1998) 1.84
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res (1990) 1.82
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Keratin classes: molecular markers for different types of epithelial differentiation. J Invest Dermatol (1983) 1.76
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res (2001) 1.67
Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res (1999) 1.65
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate (1986) 1.65
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol (2001) 1.60
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (1998) 1.59
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst (1991) 1.57
Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol (1994) 1.55
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res (1994) 1.53
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry (1984) 1.51
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Supracondylar extension fracture of the humerus in children. Manipulative reduction, immobilisation and fixation using a U-shaped plaster slab with the elbow in full extension. J Bone Joint Surg Br (2001) 1.46
Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci U S A (1998) 1.45
p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology (2001) 1.44
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ (2001) 1.43
Alcoholic neuropathy. An electrophysiological and histological study. J Neurol Sci (1970) 1.41
Gold neuropathy. Neurology (1970) 1.40
Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 1.36
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Clinical evidence for and implications of the multistep development of prostate cancer. J Urol (1990) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31
Cloning and sequencing of the 7 alpha-hydroxysteroid dehydrogenase gene from Escherichia coli HB101 and characterization of the expressed enzyme. J Bacteriol (1991) 1.29
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev (1997) 1.26
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res (1997) 1.25
Myotonia precipitated by propranolol therapy. Lancet (1977) 1.24
Gian axonal neuropathy--a generalized disorder of cytoplasmic microfilament formation. J Neuropathol Exp Neurol (1976) 1.23
PU.1, a shared transcriptional regulator of lymphoid and myeloid cell fates. Cold Spring Harb Symp Quant Biol (1999) 1.23
Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res (2001) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res (2001) 1.22
Acute idiopathic polyneuritis. A clinical and electrophsiological follow-up study. J Neurol Sci (1976) 1.22
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate (1988) 1.22
Rational basis for Trk inhibition therapy for prostate cancer. Prostate (2000) 1.22
Neuropathy associated with lymphoma. J Neurol Neurosurg Psychiatry (1971) 1.21
The sympathetic nervous system in alcoholic neuropathy. A clinical and pathological study. Brain (1975) 1.20
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res (1997) 1.20
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res (1994) 1.19
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Abnormalities of insulin secretion in dystrophia myotonica. Brain (1970) 1.18
New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology (1999) 1.18
Evoked potential changes in clinically definite multiple sclerosis: a two year follow up study. J Neurol Neurosurg Psychiatry (1982) 1.17
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 1.17
Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate (1990) 1.17
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res (1996) 1.16
Ulnar nerve lesions associated with the carpal tunnel syndrome. J Neurol Neurosurg Psychiatry (1973) 1.15
The economic status of trauma centers on the eve of health care reform. J Trauma (1994) 1.14
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res (1996) 1.14
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res (1998) 1.12
GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol (2000) 1.12
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res (1995) 1.11
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res (1999) 1.11
Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer (2001) 1.11
Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res (1997) 1.10
Protease II from Escherichia coli: sequencing and expression of the enzyme gene and characterization of the expressed enzyme. J Biochem (1991) 1.08
A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ (2002) 1.08
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate (2000) 1.07